Gene therapy is only one exciting area of treatments in the pipeline to potentially treat inherited retinal disease, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Gene therapy is only one exciting area of treatments in the pipeline to potentially treat inherited retinal disease, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Transcript
What types of treatments are being studied in the pipeline for inherited retinal disease?
We have so many exciting treatments in the pipeline for inherited retinal disease. I think in one category will be what we call gene therapy. But gene therapy is not just gene replacement therapy anymore. I think at this juncture we have the optogenetics, which is really to introduce a gene into the residual cells of the retina, and this gene will then transcribe into a protein that's light sensitive. This is for a patient with advanced inherited retinal diseases.
Another one will be the injection for what we call antisense RNA oligonucleotide treatment, and this is an intravitreal injection that corrects the problem in the messenger RNA level. That's another major breakthrough, and that still need to be tested. Then we have another particular approach, and that's CRISPR. The proof of concept, in terms of treating the patients, it's already starting.
Aside from those gene approaches, I will say there are also gene-agnostic approaches, which then we include, for example, supplementation, and there will be a NAC [N-acetylcysteine] supplementation, or you can even call it a medication treatment, that will be funded. There are also people looking at small molecules and other ways of treating inherited renal diseases. There is also a new treatment that sort of introduces small molecules and other molecules that may, in fact, draw stem cells into the retinal region. I think we have many different exciting inherited renal diseases treatment approaches.
For patients with inherited retinal diseases, what's the importance of genetic testing for diagnosis and treatment choice?
Genetic testing should be incorporated for inherited renal disease patients, because first of all, we have the approved treatment for RP65 [Luxturna, voretigene neparvovec-rzyl], and second of all, it also opens them to clinical trials. Most clinical trials require genetic confirmation of the retinal pigmentosa or other inherited retinal disease. Also, even if you don't have a study, and you don't have the approved treatment that's applicable, gene therapy still is very important in counseling the patient about the inheritance pattern, about the specific gene, about the prognosis, and that's all important in terms of treating the patient for low vision and also other supports.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More